Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HK1 | P19367 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474224 | 0.87 | MPL (0.52) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL474218 | 0.84 | RAB9A (0.69) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL474331 | 0.84 | RAB9A (0.51) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL473476 | 0.83 | RAB9A (0.53) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3147991 | 0.82 | MAPT (0.74) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL474727 | 0.76 | RAB9A (0.53) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16345828 | 0.74 | RAB9A (0.57) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6052250 | 0.74 | ALDH1A1 (0.39) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21030038 | 0.73 | RAB9A (0.53) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL475099 | 0.73 | RAB9A (0.50) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411395-B1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| EP-2411395-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109329-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | RAB9A 2462/4885MAPT 1810/4885NPC1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.